Treatment Considerations and Sequencing in Multiple Myeloma
The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.
EP: 1.The Evolving Landscape of Newly Diagnosed Multiple Myeloma
EP: 2.Highlights from ASH 2023 in Transplant-Eligible NDMM
EP: 3.Advances in the Treatment of High-Risk MM
EP: 4.Role of Transplant and MRD in Newly Diagnosed MM
EP: 5.The Evolving Treatment Paradigm for Transplant Ineligible MM
EP: 6.Treatment of Multiple Myeloma at Early Relapse
EP: 7.Potential Role for CAR T-Cell Therapy in MM at Early Relapse
EP: 8.Updates on BCMA-Targeting Bispecifics in MM
EP: 9.Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma
EP: 10.Step-Up Dosing Practices for Bispecifics in Multiple Myeloma
EP: 11.Adverse Effects Related to Bispecifics in Multiple Myeloma
EP: 12.GPRC5D-Targeting Bispecifics in Multiple Myeloma
EP: 13.CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape
EP: 14.Treatment Considerations and Sequencing in Multiple Myeloma
This is a video synopsis/summary of a Peer Exchange featuring Krina K. Patel, MD, MSc; Amrita Krishnan, MD; Caitlin Costello, MD; Saad Z. Usmani, MD, MBA, FACP; and Rafat Abonour, MD.
The discussion focuses on sequencing B-cell maturation antigen (BCMA)–targeted therapies. Continuing one BCMA bispecific antibody after progression on another may have limited efficacy due to outgrowth of BCMA loss mutations and T-cell exhaustion. A period of non-BCMA–directed therapy could help restore T-cell fitness before switching targets, like to GPRC5D with cibisatamab or teclistamab. More clinical and biologic tools are still needed to better understand resistance mechanisms among bispecific antibodies, antibody-drug conjugates, and CAR T-cell therapy to inform sequencing.
Off-the-shelf allogeneic CAR T-cell therapy could facilitate faster retreatment compared to autologous manufacturing. Continued research into optimal sequencing strategies is still needed and will be better informed by longer follow-up of currently available BCMA therapies.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
